Thanks for this.

Very interesting to read in that report that the SGLT2 inhibitor Farxiga (BMS/AZ) got the nod from the FDA in October for prevention of hospital readmissions for CHF in Type 2 diabetics. This was based on a 36% reduction in such hospitalizations in the DECLARE trial. The primary endpoint was the same as in BETonMACE, and was not significantly reduced after 4 years of follow-up. ABL reduced first hospitalizations for CHF as a prespecified secondary endpoint by 41 per cent (P=0.03). It will be interesting to learn what the FDA thinks of that.